Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.45 |
| ▸ | SGK1 | O00141 | 5/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162816 | 0.85 | CDK8 (0.45) | AXLSGK1CAMKK2CDK8PLCG1 | |
| SCHEMBL5549486 | 0.81 | CDK8 (0.42) | AXLSGK1CAMKK2CDK8PLCG1 | |
| SCHEMBL4159593 | 0.76 | AXL (0.69) | AXLSGK1CAMKK2DYRK1AMAP3K11 | |
| Bromide SCHEMBL4164915 | 0.75 | AXL (0.67) | AXLSGK1CAMKK2DYRK1AMAP3K11 | |
| SCHEMBL4167250 | 0.75 | RIPK1 (0.59) | AXLDYRK1ADYRK1BCDK8RIPK1 | |
| SCHEMBL4154787 | 0.74 | MAP3K11 (0.51) | AXLSGK1CAMKK2CLK1DYRK1A | |
| SCHEMBL4876684 | 0.71 | DEGS1 (0.58) | — | |
| SCHEMBL8321012 | 0.70 | MAPK8 (0.63) | AXLSGK1CLK1DYRK1ADYRK2 | |
| SCHEMBL22554109 | 0.70 | AXL (0.45) | AXLSGK1CAMKK2CLK1DYRK1A | |
| SCHEMBL30731289 | 0.70 | AXL (0.45) | AXLSGK1CAMKK2CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | AXL 1542/4885SGK1 1/4885CAMKK2 157/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | AXL 1432/4885SGK1 1/4885CAMKK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.